Epigenetic targeting of MECOM/KRAS axis by JIB-04 impairs tumorigenesis and cisplatin resistance in MECOM-amplified ovarian cancer. uri icon

authors

  • Singh, Ibha
  • Karna, Amarnath
  • Prajapati, Anita
  • Solanki, Ujjawal
  • Mukherjee, Archana
  • Uppal, Sheetal
  • Malhotra, Pawan
  • Manish Kumar, MD
  • Agarwal, Pallavi

publication date

  • July 15, 2025